Alto Neuroscience Files Q2 2024 10-Q

Ticker: ANRO · Form: 10-Q · Filed: 2024-08-13T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

Alto Neuroscience 10-Q filed: Q2 2024 financials out, compare to last year. Check balance sheet.

AI Summary

Alto Neuroscience, Inc. filed its 10-Q for the period ending June 30, 2024. The company, focused on pharmaceutical preparations, reported financial data for the second quarter of 2024 and the first six months of the year, comparing it to the same periods in 2023. Key financial figures and balance sheet information as of December 31, 2023, and June 30, 2024, were disclosed.

Why It Matters

This filing provides investors with an update on Alto Neuroscience's financial performance and position, crucial for understanding the company's operational health and future prospects in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As a clinical-stage pharmaceutical company, Alto Neuroscience faces inherent risks related to drug development, regulatory approvals, and market adoption.

Key Numbers

Key Players & Entities

FAQ

What were Alto Neuroscience's total revenues for the six months ended June 30, 2024?

The filing does not explicitly state total revenues for the six months ended June 30, 2024, in the provided snippet. Further review of the full 10-Q document is required.

What is Alto Neuroscience's primary business activity?

Alto Neuroscience, Inc. is classified under Standard Industrial Classification 2834, which pertains to Pharmaceutical Preparations.

When is Alto Neuroscience's fiscal year end?

Alto Neuroscience's fiscal year ends on December 31st.

What is the company's principal executive office address?

The company's business and mail address is 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, CA 94041.

What is the SEC file number for Alto Neuroscience?

The SEC file number for Alto Neuroscience is 001-41944.

From the Filing

0001999480-24-000035.txt : 20240813 0001999480-24-000035.hdr.sgml : 20240813 20240813163657 ACCESSION NUMBER: 0001999480-24-000035 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 67 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240813 DATE AS OF CHANGE: 20240813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 241202300 BUSINESS ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 10-Q 1 alto-20240630.htm 10-Q alto-20240630 12-31 0001999480 2024 Q2 False 0.4462 1.5 xbrli:shares iso4217:USD iso4217:USD xbrli:shares alto:subsidiary alto:clinical-stageAsset utr:Rate alto:tranche alto:loan xbrli:pure alto:invention alto:patentFamily utr:sqft alto:renewal 0001999480 2024-01-01 2024-06-30 0001999480 2024-08-08 0001999480 2024-06-30 0001999480 2023-12-31 0001999480 2024-04-01 2024-06-30 0001999480 2023-04-01 2023-06-30 0001999480 2023-01-01 2023-06-30 0001999480 2023-06-30 0001999480 2022-12-31 0001999480 us-gaap:CommonStockMember 2022-12-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001999480 us-gaap:RetainedEarningsMember 2022-12-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001999480 alto:SeriesBConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001999480 2023-01-01 2023-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001999480 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001999480 2023-03-31 0001999480 us-gaap:CommonStockMember 2023-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001999480 us-gaap:RetainedEarningsMember 2023-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001999480 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001999480 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001999480 us-gaap:CommonStockMember 2023-06-30 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001999480 us-gaap:RetainedEarningsMember 2023-06-30 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001999480 us-gaap:CommonStockMember 2023-12-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001999480 us-gaap:RetainedEarningsMember 2023-12-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001999480 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001999480 2024-01-01 2024-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001999480 alto:SeriesBConvertiblePreferredStockMember 2024-01-01 2024-03-31 0001999480 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001999480 2024-03-31 0001999480 us-gaap:CommonStockMember 2024-03-31 0001999480 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001999480 us-gaap:RetainedEarningsMember 2024-03-31 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001999480 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001999480 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001999480 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001999480 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001999480 us-gaap:CommonStockMember 2024-06-30 0001999480 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001999480 us-gaap:

View on Read The Filing